JP2014532412A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532412A5
JP2014532412A5 JP2014539029A JP2014539029A JP2014532412A5 JP 2014532412 A5 JP2014532412 A5 JP 2014532412A5 JP 2014539029 A JP2014539029 A JP 2014539029A JP 2014539029 A JP2014539029 A JP 2014539029A JP 2014532412 A5 JP2014532412 A5 JP 2014532412A5
Authority
JP
Japan
Prior art keywords
human
polypeptide
mhc
mouse
microglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539029A
Other languages
English (en)
Japanese (ja)
Other versions
JP6154391B2 (ja
JP2014532412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062042 external-priority patent/WO2013063346A1/en
Publication of JP2014532412A publication Critical patent/JP2014532412A/ja
Publication of JP2014532412A5 publication Critical patent/JP2014532412A5/ja
Application granted granted Critical
Publication of JP6154391B2 publication Critical patent/JP6154391B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539029A 2011-10-28 2012-10-26 遺伝子改変された主要組織適合複合体マウス Active JP6154391B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US201161552587P 2011-10-28 2011-10-28
US61/552,587 2011-10-28
US61/552,582 2011-10-28
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062042 WO2013063346A1 (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017109327A Division JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス

Publications (3)

Publication Number Publication Date
JP2014532412A JP2014532412A (ja) 2014-12-08
JP2014532412A5 true JP2014532412A5 (enExample) 2015-12-17
JP6154391B2 JP6154391B2 (ja) 2017-06-28

Family

ID=47178940

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014539029A Active JP6154391B2 (ja) 2011-10-28 2012-10-26 遺伝子改変された主要組織適合複合体マウス
JP2017109327A Active JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス
JP2019019707A Active JP6866409B2 (ja) 2011-10-28 2019-02-06 遺伝子改変された主要組織適合複合体マウス
JP2020081774A Withdrawn JP2020146041A (ja) 2011-10-28 2020-05-07 遺伝子改変された主要組織適合複合体マウス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017109327A Active JP6574457B2 (ja) 2011-10-28 2017-06-01 遺伝子改変された主要組織適合複合体マウス
JP2019019707A Active JP6866409B2 (ja) 2011-10-28 2019-02-06 遺伝子改変された主要組織適合複合体マウス
JP2020081774A Withdrawn JP2020146041A (ja) 2011-10-28 2020-05-07 遺伝子改変された主要組織適合複合体マウス

Country Status (27)

Country Link
US (3) US9615550B2 (enExample)
EP (4) EP2770821B1 (enExample)
JP (4) JP6154391B2 (enExample)
KR (3) KR101921126B1 (enExample)
CN (3) CN107254480B (enExample)
AU (3) AU2012324016C1 (enExample)
BR (1) BR112014009259A2 (enExample)
CA (2) CA2850387A1 (enExample)
CY (2) CY1119657T1 (enExample)
DK (2) DK3262932T3 (enExample)
ES (3) ES2741649T3 (enExample)
HK (1) HK1249712B (enExample)
HR (2) HRP20171761T1 (enExample)
HU (2) HUE045879T2 (enExample)
IL (3) IL232097A (enExample)
LT (2) LT3262932T (enExample)
MX (3) MX391222B (enExample)
MY (2) MY164836A (enExample)
NZ (1) NZ734532A (enExample)
PL (2) PL3262932T3 (enExample)
PT (2) PT2770821T (enExample)
RS (2) RS59082B1 (enExample)
SG (2) SG10201603188SA (enExample)
SI (2) SI2770821T1 (enExample)
SM (2) SMT201900478T1 (enExample)
WO (1) WO2013063346A1 (enExample)
ZA (1) ZA201403085B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2014249150B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules
MX368931B (es) 2013-09-23 2019-10-22 Regeneron Pharma Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
WO2015056774A1 (ja) * 2013-10-18 2015-04-23 大鵬薬品工業株式会社 Hlaクラスi発現非ヒト動物
BR112016011004A2 (pt) 2013-11-19 2017-12-05 Regeneron Pharma animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
NO2785538T3 (enExample) 2014-05-07 2018-08-04
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
KR102659123B1 (ko) 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
FI3850946T3 (fi) 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni
EP3808775B1 (en) * 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
EP3895529B1 (en) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN109456942A (zh) * 2017-09-06 2019-03-12 亘喜生物科技(上海)有限公司 通用型嵌合抗原受体t细胞制备技术
JP7139419B2 (ja) 2017-09-29 2022-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ttr遺伝子座を含む非ヒト動物および使用方法
PT3687287T (pt) 2017-09-29 2023-11-03 Regeneron Pharma Roedores que expressam complexo c1q humanizado
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2019190990A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
EP3945799A1 (en) * 2019-03-25 2022-02-09 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CA3137764A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
US20230072216A1 (en) * 2020-01-10 2023-03-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric mhc protein complex
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022133155A1 (en) * 2020-12-16 2022-06-23 Xenotherapeutics, Inc. Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs
US12376573B2 (en) 2021-03-31 2025-08-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
WO2023179620A1 (en) * 2022-03-21 2023-09-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin and mhc loci
AU2023285085A1 (en) 2022-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US20240099279A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
AU2024344227A1 (en) 2023-09-19 2026-04-30 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
JPH04501510A (ja) 1989-07-25 1992-03-19 セル ジェネシス,インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
AU728794B2 (en) 1996-03-05 2001-01-18 Scripps Research Institute, The Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
DK1017721T3 (da) 1997-09-16 2009-04-20 Univ Oregon Health & Science Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
DE69917541T2 (de) * 1998-02-17 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. H2-o modifizierte transgene tiere
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
DK1409646T3 (da) * 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
JP4830139B2 (ja) * 2006-03-10 2011-12-07 学校法人明治大学 クローン胚の作製方法
NZ547859A (en) * 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008133857A1 (en) * 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之es-細胞衍生的老鼠
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2153845A1 (en) * 2008-08-13 2010-02-17 Julius-Maximilians-Universität Würzburg Endoglin peptides, vaccines and methods for preparing the same
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
CA2913854A1 (en) * 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
WO2015056774A1 (ja) * 2013-10-18 2015-04-23 大鵬薬品工業株式会社 Hlaクラスi発現非ヒト動物
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных

Similar Documents

Publication Publication Date Title
JP7261772B2 (ja) ヒト化t細胞補助受容体を発現するマウス
AU2022221563B2 (en) Humanized t cell mediated immune responses in non-human animals
JP2014532411A5 (enExample)
JP6681939B2 (ja) ヒト化主要組織適合性遺伝子複合体を発現するマウス
JP6574457B2 (ja) 遺伝子改変された主要組織適合複合体マウス
JP2016510998A5 (enExample)
AU2020204410B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
KR20150126410A (ko) 키메라 주요 조직적합성 복합체 (mhc) 제ii부류 분자를 발현하는 유전자전이 마우스
EP4590120A1 (en) Genetically modified mice expressing components of human cellular immune system
RU2014121323A (ru) Генетически модифицированные в отношении главного комплекса гистосовместимости мыши
BR122019026475B1 (pt) Composição e método para produzir um camundongo geneticamente modificado